BerganKDV Wealth Management LLC increased its position in shares of CVS Health Co. (NYSE:CVS – Get Rating) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,887 shares of the pharmacy operator’s stock after acquiring an additional 1,577 shares during the quarter. BerganKDV Wealth Management LLC’s holdings in CVS Health were worth $2,721,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. West Bancorporation Inc. bought a new position in shares of CVS Health during the 4th quarter worth approximately $25,000. Macroview Investment Management LLC raised its stake in shares of CVS Health by 128.3% during the 1st quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock worth $25,000 after acquiring an additional 136 shares in the last quarter. Claremont Financial Group Inc. purchased a new stake in CVS Health during the 4th quarter worth approximately $26,000. Stuart Chaussee & Associates Inc. grew its position in CVS Health by 123.0% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 171 shares during the last quarter. Finally, Capital Advisors Ltd. LLC grew its position in CVS Health by 125.7% during the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock worth $33,000 after purchasing an additional 176 shares during the last quarter. Institutional investors own 78.00% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on CVS. Loop Capital began coverage on shares of CVS Health in a research report on Thursday, June 16th. They set a “buy” rating and a $120.00 target price on the stock. Sanford C. Bernstein downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $122.00 to $112.00 in a research report on Thursday, May 26th. UBS Group boosted their target price on shares of CVS Health from $118.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $113.00 to $120.00 in a research report on Thursday. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $116.90.
CVS Health Stock Performance
CVS Health (NYSE:CVS – Get Rating) last posted its quarterly earnings data on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.24. The company had revenue of $80.64 billion during the quarter, compared to analysts’ expectations of $76.38 billion. CVS Health had a net margin of 2.65% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.42 earnings per share. On average, equities research analysts forecast that CVS Health Co. will post 8.54 EPS for the current fiscal year.
CVS Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 22nd were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.15%. The ex-dividend date was Thursday, July 21st. CVS Health’s dividend payout ratio is presently 35.77%.
Insiders Place Their Bets
In other CVS Health news, EVP Alan Lotvin sold 22,541 shares of the company’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the completion of the transaction, the executive vice president now directly owns 109,183 shares in the company, valued at $11,355,032. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Thomas M. Moriarty sold 138,654 shares of the stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $95.00, for a total value of $13,172,130.00. Following the completion of the sale, the executive vice president now directly owns 626,273 shares in the company, valued at $59,495,935. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Alan Lotvin sold 22,541 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the completion of the sale, the executive vice president now owns 109,183 shares of the company’s stock, valued at $11,355,032. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by company insiders.
CVS Health Profile
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
- Get a free copy of the StockNews.com research report on CVS Health (CVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.